FDA-approved
Hormones & metabolism
Somapacitan
Evidence
FDA approved
Class
Long-acting growth hormone
KEY TAKEAWAY
Somapacitan is a growth hormone analog modified with an albumin-binding side chain so that it lasts about a week. It is sold as Sogroya. The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting growth hormone
Approved for
Growth hormone deficiency in children and adults
Key fact
The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.
Route
Weekly subcutaneous injection
Evidence strength
FDA approved
Somapacitan is a growth hormone analog modified with an albumin-binding side chain so that it lasts about a week. It is sold as Sogroya.
It activates growth hormone receptors, which raises IGF-1 and promotes growth and healthy body composition.
The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.
Growth hormone deficiency in children and adults.
Headache, injection-site reactions and joint pain are common. Higher blood sugar is possible.
U.S. FDA prescribing information for Somapacitan. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.